Showing results (301-310 of 909) with videos related to
Sort By:
Pageof 91
Archives of Internal Medicine|August 13, 2008
The hemoglobin A1c level as a progressive risk factor for cardiovascular death, hospitalization for heart failure, or death in patients with chronic heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and Morbidity (CHARM) programHertzel C Gerstein, Karl Swedberg, Jonas Carlsson, et al.Clinical Research in Cardiology : Official Journal of the German Cardiac Society|September 29, 2018
Impact of mineralocorticoid receptor antagonists on the risk of sudden cardiac death in patients with heart failure and left-ventricular systolic dysfunction: an individual patient-level meta-analysis of three randomized-controlled trialsXavier Rossello, Cono Ariti, Stuart J Pocock, et al.American Journal of Nephrology|October 28, 2019
Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease TrialGeorge L Bakris, Rajiv Agarwal, Stefan D Anker, et al.American Journal of Hypertension|November 1, 2024
Bladder Symptoms Provoked by Short, Rapid-Acting Loop Diuretics: A Frequent but Often Overlooked ProblemChristopher S Wilcox, Negiin Pourafshar, Karina Han, et al.European Journal of Heart Failure|January 17, 2025
Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by diuretic use: A FIDELITY analysisRobert J Mentz, Stefan D Anker, Bertram Pitt, et al.Clinical Journal of the American Society of Nephrology : CJASN|January 26, 2024
Sotagliflozin and Kidney Outcomes, Kidney Function, and Albuminuria in Type 2 Diabetes and CKD: A Secondary Analysis of the SCORED TrialVikas S Sridhar, Deepak L Bhatt, Ayodele Odutayo, et al.Journal of the American College of Cardiology|August 2, 2005
Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failureBertram Pitt, Harvey White, Jose Nicolau, et al.European Journal of Heart Failure|March 1, 2006
Evaluation of eplerenone in the subgroup of EPHESUS patients with baseline left ventricular ejection fraction <or=30%Bertram Pitt, Mihai Gheorghiade, Faiez Zannad, et al.ESC Heart Failure|September 18, 2025
Soluble urokinase plasminogen activator receptor and outcomes in HFpEF: A TOPCAT ancillary studyChristina G Hutten, Annika Tekumulla, Anis Ismail, et al.Circulation|September 17, 2003
Determinants of elevated pulse pressure in middle-aged and older subjects with uncomplicated systolic hypertension: the role of proximal aortic diameter and the aortic pressure-flow relationshipGary F Mitchell, Yves Lacourcière, Jean-Pascal Ouellet, et al.Pageof 91